Eikon Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Eikon Therapeutics sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 6 currently recruiting 4 completed early-phase tilt top decile by trial count

Eikon Therapeutics: 10 sponsored US clinical trials, 6 recruiting.

Eikon Therapeutics sponsors 10 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumors, with 2 trials.

Top-decile sponsor footprint

Eikon Therapeutics ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NCT07365319
RECRUITING Phase 1

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619
RECRUITING Phase 2

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301
RECRUITING Phase 1

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043
RECRUITING Phase 2

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

NCT06246110
RECRUITING Phase 1

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130
COMPLETED Phase 2

BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors

NCT04819373
COMPLETED Phase 1

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

NCT04840394
COMPLETED Phase 1

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

NCT04196530
COMPLETED Phase 1

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

NCT03486301

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 4

Therapeutic Areas

Advanced Solid Tumors 2
Mismatch Repair Deficient or MSI-High Solid Tumors 1
MSI-H/dMMR Gastroesophageal-junction Cancer 1
MSI-H/dMMR Colorectal Cancer 1
MSI-H/dMMR Gastric Cancer 1
MSI-H or dMMR Advanced Solid Tumors 1
Advanced Melanoma 1
Tumor, Solid 1
NSCLC 1
Endometrial Cancer 1

What is open in the Eikon Therapeutics pipeline

6 recruiting of 10 indexed (60% open); 4 completed (40%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Advanced Solid Tumors (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Eikon Therapeutics: open-pipeline peers nationwide

Peers matched on 10 registered trials and 60% open enrollment, not the therapeutic-area sidebar.

Eikon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 4681012 0%20%40%60%80% Total trials Recruiting share Eikon TherapeuticsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAlaska Native Tribal Health ConsortiumAnwaar SaeedAutolus LimitedBeam Therapeutics
Eikon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Eikon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 60% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Eikon Therapeutics page

10 registered trials is a research-attention snapshot, not an endorsement of Eikon Therapeutics or any single study.

  • 6 of Eikon Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Advanced Solid Tumors is the condition Eikon Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eikon Therapeutics pipeline card: 10 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.